NDLI: Mapreg : Toward a novel approach of neuroprotection and treatment of Alzbeimerś disease

Content Provider	Springer Nature Link
Author	Baulieu, Etienne Emile Robel, Paul Fellous, Arlette Duchossoy, Yann Fontaine Leir, Virginie David, Sebastien
Copyright Year	2004
Abstract	MAPREG (microtubule-associated protein/neurosteroidal pregnenolone) is a start-up company that was created in October 2000. Its acronym recalls the basic discovery (Murakami et al., 2000) from which drug(s) will hopefully be developed that are useful for neuroprotection and repair in conditions such as post-traumatic and postischemic lesions, as well as defects proper to normal aging and neurodegenerative diseases, that is, principally Alzheimer’s disease. Pregnenolone, the main steroid synthesized from cholesterol in the nervous system (therefore, a neurosteroid), binds specifically with high affinity (≥40 nM) to microtubule-associated protein 2 (MAP2), a protein family involved in the assembly and stabilization of microtubules made from tubulin α and β polymers, and in the bundling of several microtubules by MAP2 projection arms. Pregnenolone binding increases MAP2-induced microtubule polymerization, when purified tubulin and MAP2 are coincubated in GTP containing buffer at 37°C. Therefore, MAP2 can be considered as a receptor for a novel mechanism of steroid action. The underlying principle and its potential pharmacological consequences are described in an INSERM patent (FR 0003430; March 17, 2000) (see Fig. 1).MAPREG has established its own laboratory in a space rented to Bicêtre hospital, near the research building of INSERM, where two of the main founders of the company (Drs. E. Baulieu and P. Robel) work. The company has been quite successful, largely thanks to the support of ISOA (attributed in October 2002). A lead compound (pregnenolone derivative) was tested and patented by MAPREG early in 2003 (FR 0300507; January 17, 2003). Activities and results reported at the ISOA meeting on Oct. 2, 2003, include in vitro basic studies, in vitro and in vivo neuroprotection trials in rodent systems, and studies with human cells and an AD transgenic mouse model.
Starting Page	63
Ending Page	65
Page Count	3
File Format	PDF
ISSN	08958696
Journal	Journal of Molecular Neuroscience
Volume Number	24
Issue Number	1
e-ISSN	15591166
Language	English
Publisher	Humana Press
Publisher Date	2004-01-01
Publisher Place	Totowa
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Neurosciences Neurology
Content Type	Text
Resource Type	Article
Subject	Medicine Cellular and Molecular Neuroscience

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Induction of NQO1 and Neuroprotection by a Novel Compound KMS04014 in Parkinson’s Disease Models

Erythropoietin: Novel Approaches to Neuroprotection in Human Brain Disease

Immunological approach for the treatment of Alzheimer’s disease

NAP mechanisms of neuroprotection

The Novel Cholinesterase–Monoamine Oxidase Inhibitor and Antioxidant, Ladostigil, Confers Neuroprotection in Neuroblastoma Cells and Aged Rats

A new concept in the pharmacology of neuroprotection

White matter disease: A novel approach to treatment of neuromyelitis optica.

Calpain inhibitors : A treatment for alzheimer’s disease

Potent Protection Against MPP$^{+}$-Induced Neurotoxicity via Activating Transcription Factor MEF2D by a Novel Derivative of Naturally Occurring Danshensu/Tetramethylpyrazine

Mapreg : Toward a novel approach of neuroprotection and treatment of Alzbeimerś disease

Similar Documents

Induction of NQO1 and Neuroprotection by a Novel Compound KMS04014 in Parkinson’s Disease Models

Erythropoietin: Novel Approaches to Neuroprotection in Human Brain Disease

Immunological approach for the treatment of Alzheimer’s disease

NAP mechanisms of neuroprotection

The Novel Cholinesterase–Monoamine Oxidase Inhibitor and Antioxidant, Ladostigil, Confers Neuroprotection in Neuroblastoma Cells and Aged Rats

A new concept in the pharmacology of neuroprotection

White matter disease: A novel approach to treatment of neuromyelitis optica.

Calpain inhibitors : A treatment for alzheimer’s disease

Potent Protection Against MPP$^{+}$-Induced Neurotoxicity via Activating Transcription Factor MEF2D by a Novel Derivative of Naturally Occurring Danshensu/Tetramethylpyrazine

Mapreg : Toward a novel approach of neuroprotection and treatment of Alzbeimerś disease